Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

NCT06105021 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma
Non-Small Cell Lung Cancer
Colorectal Cancer
Solid Tumor
KRAS G12V

Interventions

DRUG: AFNT-211

Sponsor

Affini-T Therapeutics, Inc.